Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administration-approved medications for FTD although symptomatic treatments such as selective serotonin reuptake inhibitors and atypical antipsychotic agents are frequently used to manage behavioral abnormalities associated with this disorder. Evidence for the use of currently available symptomatic treatments in each FTD clinical subtype is reviewed. In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citationReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“Recent evidence suggests that reducing tau expression may also be a viable therapeutic strategy for tau-related neurodegenerative disorders.(94,95) The variability of underlying tau-related neuropathology in fvFTD may limit the utility of tau-directed disease-modifying therapies until more specific biomarkers for tau…”
BackgroundCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 1×
“A significant proportion of cases of fvFTD, in most cases without MND,(76) have been found to have loss of function mutations in the progranulin (PRGN) gene.(77,78) Progranulin is a peptide growth factor that plays important roles in mediating neuronal development and inflammation.”
BackgroundImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“Strategies for normalizing expression of (or overexpressing) individual central nervous system proteins have been validated in human AD patients, suggesting that the technology for normalizing regional progranulin expression may be close at hand.(86) Finally, the identification of concurrent a-synuclein and/or AD path…”
BackgroundTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“Finally, the identification of concurrent a-synuclein and/or AD pathology in a number of PGRN families with onset of symptoms as late as 75 years of age,(84,87) the identification of TDP-43 pathology in approximately 20% of AD cases, and other possible roles for progranulin in mediating neuroinflammation in AD,(79) ra…”
BackgroundNoble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 1×
“Transgenic mouse and Drosophila models of a number of pathogenic tau mutations exist and are facilitating the development of potential disease-modifying agents that alter the phosphorylation of tau, such as lithium(90,91) and interventions that affect the folding and metabolism of tau.(92,93) Recent evidence suggests…”
BackgroundThe evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Clinicopathological correlates in frontotemporal dementia
Hodges, J. R., Davies, R. R., Xuereb, J. H., Casey, B., Broe, M., Bak, T. H., Kril, J. J., & Halliday, G. M. (2004) · Annals of Neurology · doi:10.1002/ana.20203 · Cited by 580
Cited by
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationFrontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 501
Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management
Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70299-4 · Cited by 496
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Self-citationClinical features and multidisciplinary approaches to dementia care
MacDonald, S., Grand, & Caspar (2011) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s17773 · Cited by 254
Metadata
- Authors
- Boxer, A. L., & Boeve, B. F.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2007-10
- Volume
- 21
- Issue
- 4
- Pages
- S79-S87
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W1974607943
- Cited by
- 88
- References
- 25
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. https://app.cochat.ai/papers/10.1097/wad.0b013e31815c345e
- The paper
- Boxer, A. L., & Boeve, B. F. (2007). Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0b013e31815c345e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.